🔎 Trials Near Me

Acasă › Leucemie mieloasă acută › Texas

Studii clinice pentru Leucemie mieloasă acută în Texas

94 studii pentru Leucemie mieloasă acută caută participanți în Texas.

Orașe în Texas

Text oficial al studiului (în engleză)

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  • The University of Texas MD Anderson Cancer Center /ID# 279402, Houston
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07581002

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • The Don and Sybil Harrington Cancer Center, Amarillo
  • UT MD Anderson Cancer Center, Houston
  • Audie L Murphy VA Hospital, San Antonio
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Texas Children's Hospital, Houston
În curs de recrutareStudiu observațional
Vârste de la 0 la 38 · Toate sexele · Actualizat 1 oct. 2026 · NCT06131801

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • University of Texas MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de la 12 la 78 · Toate sexele · Actualizat 29 sept. 2026 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Baylor University Medical Center, Dallas
  • Houston Methodist Cancer Center, Houston
  • MD Anderson Cancer Center, Houston
  • și încă 2
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390

Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT03629171

A Phase 1B/2A Trial of NADUNOLIMAB in Combination With Azacitidine (With/Without Venetoclax) in Patients With Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML)

  • MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06548230

Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation

  • Clinical Trial Site, Houston
În curs de recrutareFaza 3
Vârste de 12 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT07211958

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

  • UT Southwestern/Simmons Cancer Center-Dallas, Dallas
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT03874052

Quizartinib, Decitabine, and Venetoclax in Treating Participants With Untreated or Relapsed Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT03661307

A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2Voluntari sănătoși bineveniți
Vârste de 12 ani și peste · Toate sexele · Actualizat 23 sept. 2026 · NCT05360160

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center, Houston
  • Ben Taub General Hospital, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

  • The University of Texas M. D. Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT06769490

Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT03214562

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

  • MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT06284486

Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de 1 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT03630991

Clinical Study of Anti-FLT3 CAR-T Cells for the Treatment of Relapsed/Refractory AML

  • MD Anderson, Houston
În curs de recrutareFaza 1
Vârste de 12 ani și peste · Toate sexele · Actualizat 17 sept. 2026 · NCT06786533

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • și încă 9
În curs de recrutareFaza 3
6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562

Chimeric Antigen Receptor Treatment Targeting CD70 (SEVENTY)

  • Texas Children's Hospital, Houston
  • The Methodist Hospital, Houston
În curs de recrutareFaza 1
Până la vârsta de 75 · Toate sexele · Actualizat 16 sept. 2026 · NCT06345027

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • The Methodist Hospital Research Institute, Houston
  • The University of Texas MD Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT06824168

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

  • The University of Texas MD Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 15 sept. 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT03471260

Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT03683433

A Study of BGB-11417 in Participants With Myeloid Malignancies

  • Md Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 14 sept. 2026 · NCT04771130

A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

  • The University of Texas MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT06616636

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT06969430

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • Children's Medical Center Dallas /ID# 275930, Dallas
În curs de recrutareFaza 1
6 Months – 17 Years · Toate sexele · Actualizat 9 sept. 2026 · NCT07306832

ASTX727, Venetoclax, and Gilteritinib for the Treatment of Newly Diagnosed, Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT05010122

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • și încă 1
În curs de recrutareFaza 3
Vârste de la 1 la 25 · Toate sexele · Actualizat 4 sept. 2026 · NCT07022678

Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 12 ani și peste · Toate sexele · Actualizat 4 sept. 2026 · NCT03383575

A Phase Ia/Ib Open-label, Multiple Dose, Study to Determine the Recommended Dose, Evaluate PKs, PDs, Safety, and Activity of Venetoclax in Combination With Oral Decitabine/Cedazuridine (ASTX727) in Pediatric Patients With Relapsed/Refractory Acute Myeloid Leukemia (AML)

  • MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de la 2 la 18 · Toate sexele · Actualizat 4 sept. 2026 · NCT06191978

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

  • Baylor Scott & White Health, Dallas
  • MD Anderson, Houston
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 3 sept. 2026 · NCT04588922

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

  • US-Dallas TX-SOUTHWESTERN, Dallas
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 sept. 2026 · NCT06652438

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  • The University of Texas MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de la 18 la 85 · Toate sexele · Actualizat 26 aug. 2026 · NCT06834282

CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome

  • M D Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT04493164

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • MD Anderson Cancer Center, Houston
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT06533761

Monitoring, Detoxifying, and Rebalancing Metals During Acute Myeloid Leukemia (AML) Therapy, a Phase 2 Randomized Study

  • The University of Texas M. D. Anderson Cancer Center, Houston
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT06811233

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Dell Children's Medical Center of Central Texas, Austin
  • Driscoll Children's Hospital, Corpus Christi
  • Medical City Dallas Hospital, Dallas
  • și încă 10
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.